Breaking News

Skye Bioscience Licenses Halozyme’s ENHANZE Drug Delivery Technology

Will support Skye's evaluation of higher nimacimab subcutaneous doses for the treatment of obesity.

Author Image

By: Charlie Sternberg

Associate Editor

Halozyme Therapeutics Inc. and Skye Bioscience Inc. have entered a non-exclusive global collaboration and license agreement under which Skye will license Halozyme’s ENHANZE drug delivery technology for the development and potential commercialization of a subcutaneous formulation of nimacimab for the treatment of obesity. The collaboration is intended to support Skye’s evaluation of higher nimacimab subcutaneous doses through delivery of larger injection volumes. “Our collabo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters